Vanda Pharmaceuticals Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ 262.16, 356.5, 425.43, 509.13, 563.67 ], "ebit_estimate": [ -147.8, -61.05, -50.13, 7.67, 63.77 ], "ebitda_estimate": [ 11.9, null, null, null, null ], "net_income_estimate": [ -135.48, -54.96, -44.67, -3.3, 44 ], "per_share_eps_estimate": [ -2.27, -0.77, -0.63, -0.05, 0.68 ], "eps_nri_estimate": [ -2.27, -0.77, -0.63, -0.05, 0.68 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null ], "pretax_income_estimate": [ -138.28, -55.8, -46, 3.17, 66.53 ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null ], "roa_estimate": [ -42.8, -27, null, null, null ], "roe_estimate": [ -75, -51.6, null, null, null ], "gross_margin_estimate": [ 94, 94, null, null, null ], "operating_cash_flow_estimate": [ null, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, 9.22 ], "long_term_growth_rate_mean": 47.48, "long_term_revenue_growth_rate_mean": "26.36", "future_per_share_eps_estimate_growth": 47.48, "future_eps_nri_estimate_growth": 47.48, "future_revenue_estimate_growth": 26.36, "future_ebit_estimate_growth": 34.26, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": 43.4, "future_pretax_income_estimate_growth": 34.12, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712" ], "revenue_estimate": [ 61.93, 69.15, 79.23, 80.5, 86.5, 91, 96 ], "ebit_estimate": [ -38.32, -34.28, -30.78, -20.9, -12.4, -4.9, 3.6 ], "ebitda_estimate": [ null, null, null, null, null, null, null ], "net_income_estimate": [ -34.94, -30.55, -21.85, -19.6, -11.4, -4, 3.5 ], "per_share_eps_estimate": [ -0.59, -0.51, -0.36, -0.28, -0.15, -0.06, 0.03 ], "eps_nri_estimate": [ -0.59, -0.51, -0.36, -0.28, -0.15, -0.06, 0.03 ], "dividend_estimate": [ null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null, null, null ], "pretax_income_estimate": [ -35.42, -31.68, -23.13, -19.6, -11.4, -4, 4.4 ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null, null, null ], "roa_estimate": [ -10.2, -9.7, -7.4, -9.1, -6.1, -5.6, -4.3 ], "roe_estimate": [ -16, -16.1, -13, -15.5, -10.9, -10.4, -8.3 ], "gross_margin_estimate": [ 94, 94, 94, 94, 94, 94, 94 ], "operating_cash_flow_estimate": [ null, null, null, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, null, null, null ], "long_term_growth_rate_mean": 47.48, "long_term_revenue_growth_rate_mean": "26.36", "future_per_share_eps_estimate_growth": 47.48, "future_eps_nri_estimate_growth": 47.48, "future_revenue_estimate_growth": 26.36, "future_ebit_estimate_growth": 34.26, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": 43.4, "future_pretax_income_estimate_growth": 34.12, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }